Integrated DNA Technologies Announces Translational CRISPR Portfolio Expansion with Product Innovation Updates
'IDT's rich history, deep expertise, and ability to manufacture bespoke products at the highest quality uniquely positions us to consistently innovate on our CRISPR portfolio and support customers at every stage of their gene editing journey'
Share
Tailored gRNAs to Accelerate CRISPR Discoveries
As researchers advance from discovery to clinical applications, the demand for higher purity in CRISPR reagents increases. To meet this need, IDT's chemically synthesized gRNAs are now available for online ordering in a range of modification and purity options. With high purity ideal for translational applications such as gene editing in primary cells and in vivo models, IDT's high-performance liquid chromatography (HPLC)-purified gRNAs are orderable in 2 nmol and 10 nmol yields with larger quantities available by request and ship in as little as 12 business days. Formats include CRISPR-Cas9 gRNA and Custom Alt-R™ CRISPR gRNA. 2' Fluoro, 2' O-Methyl, and other modifications can be added to increase stability and specificity with IDT's custom gRNA tool.
Supporting Scientists with Regulatory Filings and Ensuring Safety of Therapeutic Candidates
CRISPR-based genome editing allows for targeted editing at specific sites in the genome, but there is potential risk that off-target edits at other locations can occur. To enable scientists to understand where these off-target edits might happen and assess how they might impact safety early in the therapeutic development process, IDT launched UNCOVERseq, off-target nomination services which uses an enhanced GUIDE-seq™ methodology to identify off-target sites for its customers. When paired with IDT's award-winning off-target confirmation services, rhAmpSeq™ CRISPR Analysis System, CRISPR pioneers can confidently accelerate their path to the clinic by obtaining a deeper understanding of editing risks.
The custom safety services provided in baby KJ's treatment helped launch UNCOVERseq and represent a major step forward in ensuring the safety of CRISPR-based therapies.
Enhancing Safety, Quality and Efficiency: IDT's Growing Pipeline and Future Collaborations
Future IDT launches, planned for late 2025, include complementary offerings such as the Alt-R HDR Enhancer Protein, which is designed specifically for therapeutic applications, and manufactured by Aldevron, to meet rigorous quality standards. The HDR Enhancer Protein improves HDR efficiency in difficult-to-edit cells, and maintains safety and cell health. IDT, in collaboration with Aldevron, will also be launching a novel Cas9 mRNA to support early discovery to clinical stage customers. IDT has been a long-time provider of CRISPR gRNA libraries for screening applications and will unveil a new design tool later this year for efficient ordering of custom, configured libraries.
'IDT's rich history, deep expertise, and ability to manufacture bespoke products at the highest quality uniquely positions us to consistently innovate on our CRISPR portfolio and support customers at every stage of their gene editing journey,' said Sandy Ottensmann, VP/GM, Gene Writing & Editing at IDT. 'On the heels of the world's first personalized CRISPR-based therapy, we're honored to bring more CRISPR tools that will enable researchers to make important discoveries, like the one designed for baby KJ, and progress science forward.'
Learn more about IDT's CRISPR portfolio here.
About IDT
Building from a strong foundation of innovation, expertise, and reliability, Integrated DNA Technologies (IDT) has evolved from an oligo manufacturer to a leading genomics provider. We work shoulder-to-shoulder with scientific and global health partners to enable genomics breakthroughs at scale. Our vision of enabling researchers to rapidly move from the lab to life-changing advances reflects our ongoing commitment to a healthier, brighter future for all.
IDT is proud to be part of Danaher, a global science and technology leader. Together we combine our capabilities to accelerate the real-life impact of tomorrow's science and technology to improve human health.
For more information about IDT, visit www.idtdna.com and follow the company on LinkedIn, X, Facebook, YouTube, and Instagram.
Disclaimer: RUO — For research use only. Not for use in diagnostic procedures. Unless otherwise agreed to in writing, IDT does not intend these products to be used in clinical applications and does not warrant their fitness or suitability for any clinical diagnostic use. Purchaser is solely responsible for all decisions regarding the use of these products and any associated regulatory or legal obligations.
Disclaimer: CGMP refers to products manufactured under ICHQ7; IDT engineering runs and CGMP gRNA are for development and investigational use only. The performance characteristics of this product have not been established. This product is not intended to be used as final drug product. The purchaser is solely responsible for all decisions regarding the intended use of the product and any associated legal or regulatory obligations.
GUIDE-seq™ is owned by Maxcyte®, Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
22 minutes ago
- Business Wire
Mountain Valley MD Provides Business Update, Advances Commercialization Strategies
TORONTO--(BUSINESS WIRE)--Mountain Valley MD Holdings Inc. (the 'Company' or 'MVMD') (CSE: MVMD) (OTCQB: MVMDF) (FRA: 20MP) is pleased to provide a business update on its commercialization progress across its three core areas of focus: Nutraceuticals – Innovations through the Company's Quicksome™ technology, designed to improve the administration and efficacy of nutraceutical health and wellness products; Agriculture – The Company's licensed Agrarius agricultural plant signaling technology, designed to organically drive increased crop yields, reduce fertilizer and pesticide usage where desired, and enhance plant health; and Husbandry Animals/Aquatic Species – The application of solubilized drug formulations through the Company's Quicksol™ technology, designed to positively impact the health of husbandry animals and aquatic species. 'In recent months, we have focused on measured execution across all business lines,' said Dennis Hancock, President & CEO of Mountain Valley MD. 'We continue to advance the commercial foundations needed to bring our technologies to market at scale, supported by progress in field trials and product launches.' NUTRACEUTICALS Quicksome™ Technology, Commercialization, and Business Development Progress MVMD's patented liposomal Quicksome™ technology uses proprietary formulations and stabilizing agents to encapsulate active ingredients with the goal of optimizing molecule delivery in sublingual nutraceutical applications. The Company's Quicksome™ technology is currently focused on delivering molecules where enhanced efficacy, precise dosing, reduced variability, and dose sparing are valued. 'Our Quicksome™ technology has proven adaptable across multiple product formulations,' Mr. Hancock noted. 'We believe the platform's dose-sparing benefits and demonstrated efficacy versus orally consumed competitors will continue to attract new partners and product opportunities in this scaled commercialization phase.' MVMD continues to advance its nutraceutical strategy through its exclusive manufacturing and licensing arrangement with a U.S.-based GMP production partner (the 'Lead Manufacturer'). The Lead Manufacturer has GMP and OTC drug manufacturing capabilities and has installed proprietary equipment for producing MVMD's Quicksome™ sublingual and dermal formulations. The Lead Manufacturer works closely with the Company to complete product and production elements necessary to support it's obligations under MVMD's license agreement with Circadian Wellness Corp. ('Circadian'), an MVMD licensee, as well as MVMD's proprietary 'Mountains Of…' product line and other business development initiatives. During the first half of the 2025 calendar year, MVMD and its Lead Manufacturer supported the scaled-up production and market launch of Circadian's 'Eons Dialed,' a sublingual product for anxiety support. Circadian's product line, which includes 'Eons Deeper Sleep' and 'Eons Dialed,' is manufactured by the Lead Manufacturer and incorporates Quicksome™ technology. Circadian reported positive consumer reception to its Quicksome™-based products, including USD $193,000 in sales during April to June 2025, a notable increase from prior periods. In parallel, MVMD is engaged in business development initiatives with the Lead Manufacturer to secure additional nutraceutical licensing partnerships. A key project the Company has been advancing involves a U.S.-based multi-level marketing client (the 'MLM Client') for a novel fenugreek glycosides testosterone formulation. The Lead Manufacturer has secured distribution rights for a standardized ingredient with clinically demonstrated effects on total and biologically active free testosterone. The product has been successfully integrated into a Quicksome™ quick-dissolve tablet, and has supported testosterone levels in male subjects through documented trials. Human testosterone levels are well documented to positively impact muscle mass, strength, energy, vitality, libido, and spermatogenesis. The MLM Client has completed multiple rounds of product feedback regarding dissolution and flavor, with commercial terms anticipated in calendar 2025. A white-label version is also planned for manufacturing for broader distribution in the current calendar quarter. MVMD has also completed development of additional formulations for energy, lean metabolism, focus, stress, and anxiety support. These are available for manufacturing through the Lead Manufacturer and are intended to support MVMD's branding and additional business development efforts through the remainder of calendar 2025. The Company's nutraceutical pipeline also includes active development projects for hematological health, nutritional support, hydration and performance, joint health, and pain management. The Company's 'Mountains Of…' proprietary brand has secured U.S. trademark protection for multiple product categories (Sleep, Energy, Relief, Libido, Lean) to support GMP product sample development and business development activities. Distribution partners may elect to market MVMD's 'Mountains Of…' products or produce proprietary versions with their own branding. AGRICULTURE Agrarius Business Development and Commercialization Progress 'We believe the results of our collaboration with agronomists and agricultural partners throughout Latin America continue to validate the numerous Agrarius benefits across major crop types in diverse real-world conditions,' Mr. Hancock stated. 'We view being intentional with our data-driven approach as being the foundation for long-term adoption and meaningful commercial growth.' MVMD has been working to advance commercialization in its agricultural division, which is focused on the licensed distribution of the Agrarius plant signaling technology. Under its exclusive license agreement with Agrarius Corp. ('AC'), MVMD holds the exclusive rights to sell the Agrarius product throughout North America, Mexico, Central America, South America, and the Caribbean (the 'Exclusive Territory'). While MVMD does not manufacture the product, it facilitates regional regulatory approvals, product trials, import logistics, business development, and commercial distribution across the Exclusive Territory. The Agrarius product is mixed either with water or with other agricultural products, such as fertilizers, pesticides, or herbicides, at the point of application and then applied via sprayer to agricultural crops at ideal times during a plant's lifecycle. Agrarius has been tested across numerous major agricultural crops and has demonstrated its ability to naturally increase crop yields with results varying depending on crop type, reduce fertilizer usage, and increase general resilience to pests and climate change forces such as drought. The Company is entering what it characterizes as a new phase of its validation and commercialization strategy in the Exclusive Territory, in particular in Latin America (LATAM), following the completion of an initial cycle of professional field trials in Brazil across key crops - including corn, sugarcane, soybeans, potatoes, and citrus - alongside an extensive evaluation program with soybean farmers in high-productivity environments. The Company's agronomists have been working closely with certified third-party agricultural testing partners, academic institutions, and farmers to conduct product trials, including extensive metabolic and physiological analysis studies for Agrarius-treated crops. The Company believes that recent trial results continue to validate the efficacy of the Agrarius product and will support its planned product adoption and broad commercialization strategy. A sample of recently achieved key trial outcomes, includes: Corn: In a study conducted by UNESP (Universidade Estadual Paulista), Agrarius application led to improved physiological conditions, higher chlorophyll concentrations, and increased root systems. This resulted in a yield increase of 14.8% in the Dourados region and 11.2% in the Santa Cruz area in Brazil. Sugarcane: Trials conducted by Agroquatro A.S, a company in Brazil that promotes and markets plant nutrition products, demonstrated a significant yield improvement of 8 to 12 tons per hectare (approximately 10%), a 15% increase in sugar yield, and a 47% reduction in damage caused by pests. Soybeans: Across 14 validation trials with farmers in Brazil, the application of Agrarius resulted in an average yield increase of 6.34 sacs per hectare. Notably, one high-performance producer participating in the Brazilian Soybean Strategic Committee ('CESB') Competition achieved a 15.61% productivity gain, yielding 117.93 bags/ha with Agrarius versus 102 bags/ha without. Potatoes: A field test harvested in June 2025 showed a productivity increase of 18.49%, with the Agrarius-treated area yielding 51,250 Kg/Ha compared to the control area's 43,250 Kg/Ha. Citrus: Preliminary results from trials on mature Hamlin orange trees showed a productivity increase of 5.29%. Satellite data analysis from the Company's contracted satellite monitoring subscription, OneSoil, visually shows a potential productivity improvement of up to 15% that will be assessed physically in the final harvest. This is consistent with previous trials the company conducted on citrus in Costa Rica. 'The results we are seeing from Agrarius trials in Latin America confirm to us its performance in diverse real-world conditions,' continued Mr. Hancock. 'Completing effective Agrarius trials helps build the confidence needed for larger agricultural operators to continue evaluating the impact of successfully integrating Agrarius more broadly into their operations.' The Company has commenced additional professionally managed testing protocols on cotton, coffee, and citrus, along with a second cycle for sugarcane and broad farmer-led validations for wheat and barley that would mirror what was recently accomplished with soybean trialing. In Colombia, MVMD has commenced a grass productivity program in partnership with FEDEGAN, the national cattle growers' federation, which supports agricultural farms covering approximately 43 million hectares of cattle pastures. The study spans seven regions and targets productivity, nutritional content, and growth cycles on different grass types when Agrarius is applied versus control groups. The trial is being managed in coordination with local agronomists and technical directors, and is expected to run through calendar 2026, with preliminary results anticipated in the 2025 calendar year. The initial trialing and business development efforts the Company has been conducting with its third-party research partners and initial agricultural prospects has provided clarity to management that it is more likely that large-scale clients will require several cycles of crop trialing experience with Agrarius before more broadly adopting the Agrarius product in a meaningful scale in their operation. Operationally, the Company completed its first trial import and clearance of its product samples into Brazil through its Panamanian logistics partner located in the Pana Park duty-free zone. This process established the customs and fiscal structure necessary for potential future larger-scale commercial shipments into Brazil. MVMD continues to manage regulatory filings across the Exclusive Territory and has secured registration in Canada, Brazil, Colombia, Panama, Bolivia, Peru and most of the US states. Additional filings are in process for Mexico, Costa Rica, and Uruguay. To protect the Agrarius brand, MVMD has filed trademark applications in thirteen key jurisdictions across LATAM. The Performance Guarantee Program ('PGP') remains a central element of MVMD's go-to-market strategy. Under the program, participating clients only pay for product after achieving defined performance thresholds. The Company believes this model has effectively reduced hesitation in early adoption for testing purposes, while generating valuable field data. MVMD and AC share the risk of performance, with AC deferring payment from MVMD until the PGP performance obligations are met. The Company believes this structure will drive revenue conversion as it scales into more significant field applications across the Exclusive Territory and is working with AC to understand how it will manage PGP opportunities in LATAM against current business development activity. 'The combination of consistent trial results, expanding regulatory approvals, and the Performance Guarantee Program is intended to position Agrarius for scaled adoption,' Mr. Hancock said. 'We view these as the key steps that will move us from testing into commercial use.' HUSBANDRY ANIMALS / AQUATIC SPECIES Soluvec™ 1% Product Progress in Bangladesh, Other Market Targets MVMD has applied its Quicksol™ solubilization technology to Ivermectin to create its Soluvec™ 1% formulation, which the Company designed to provide a safer and more effective solution for broad administration across husbandry animals and aquatic species. The Soluvec™ 1% formulation has been documented to have a nine-month stability at both room and refrigerated temperatures through a third-party Contract Manufacturing Operator in the United States. The Company's primary commercialization approach is to license this technology to third parties. MVMD previously entered into a license agreement for Soluvec™ 1% animal husbandry applications in Bangladesh with a privately held Ontario corporation holding exclusive rights to manufacture and distribute Soluvec™ 1% products in injectable and feed coating formats in Bangladesh. Under this agreement, MVMD earns a royalty on net sales in the region. As of July 2025, the Licensee has produced approximately 200 tonnes of Soluvec™ 1% coated fish feed distributed through five local distributors. Royalty revenues have been below management's expectations, impacted in part by damage to the farmed fishing industry from Cyclone Remal in 2024. MVMD has communicated performance concerns to it's licensee and will monitor sales over the coming quarters. Global interest in Soluvec™ remains positive in management's view. In an effort to grow future Soluvec™ 1% formulation royalties, MVMD intends to accelerate broader commercialization efforts across Latin America and other emerging markets in future quarters. The Company has filed for patent protection in 12 additional markets outside of the United States, including Canada, China, India, Mexico, Sri Lanka, Thailand, Philippines, Malaysia, Brazil, Peru, Argentina, and Chile. The Company's published peer-reviewed study data in the journal Therapeutic Delivery supports the improved bioavailability, efficacy, and potential cost savings of Soluvec™ for both animals and potentially human health applications. 'Soluvec™ continues to demonstrate to us its measurable advantages in stability, bioavailability, and application,' said Mr. Hancock. 'Our priority is to support the existing licensee in Bangladesh while advancing expansion into additional markets where our patents support strategic capital deployment.' ABOUT MOUNTAIN VALLEY MD HOLDINGS INC. Mountain Valley MD is building a world-class organization centered around the implementation, licensing and reselling of key technologies and formulations: patented Quicksome™ oral formulation and delivery technologies, patented Quicksol™ solubility formulation technology licensed product reseller of Agrarius™, a novel agricultural plant signaling technology Consistent with its vision towards 'More Life', MVMD applies its owned and licensed technologies to its work for advanced delivery of molecules for human and husbandry animal applications, including the development of products for pain management, weight loss, energy, focus, sleep, anxiety, and more. Additionally, MVMD's work with Agrarius is focused on generating a positive impact on crop yields and reducing fertilizer usage. MVMD's patented Quicksome™ technology utilizes proprietary formulations and stabilizing molecules to encapsulate and formulate active ingredients into highly efficient product formats. The result is a new generation of product formulations that could be capable of delivering nutraceutical and drug molecules into the body faster, with greater impact, efficiency and accuracy. MVMD's patented Quicksol™ technology covers all highly solubilized macrocyclic lactones that could be effectively applied in multiple viral applications that could positively impact human and animal health globally. MVMD's licensed Agrarius™ agricultural plant signaling technology is designed to be applied to crops to naturally increase yields, reduce fertilizer usage, and increase general resilience to pests and climate change. For more Company information and contact details, visit SOURCE: Mountain Valley MD Holdings Inc. CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION Certain statements contained in this news release may constitute forward-looking information. Forward-looking information is often, but not always, identified by the use of words such as "anticipate", "plan", "estimate", "expect", "may", "will", "intend", "should", and similar expressions. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking information. The Company's actual results could differ materially from those anticipated in this forward-looking information as a result of regulatory decisions, competitive factors in the industries in which the Company operates, prevailing economic conditions, and other factors, many of which are beyond the control of the Company. The Company is making forward-looking statements, including but not limited to: the continued interest of third parties in the Quicksome™ technology and the timing thereof; that recent Agrarius trial results will support the planned production adoption and broad commercialization strategy; future testing/trials, including timing, locations and products (of Agrarius); the PGP and the results and impact thereof; and the monitoring of licensee operations in Bangladesh and the timing thereof. The Company believes that the expectations reflected in the forward-looking information are reasonable, but no assurance can be given that these expectations will prove to be correct and such forward-looking information should not be unduly relied upon. Any forward-looking information contained in this news release represents the Company's expectations as of the date hereof and is subject to change after such date. The Company disclaims any intention or obligation to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required by applicable securities legislation. Neither the CSE nor OTC has reviewed or approved the contents of this press release.
Yahoo
42 minutes ago
- Yahoo
Ontario Expands Access to Dexcom G7 CGM Under the Ontario Drug Benefit (ODB) Program
New Ontario Drug Benefit (ODB) coverage means eligible Ontarians who take insulin can now benefit from using Dexcom G7 to simplify management of their diabetes. BURNABY, British Columbia, July 30, 2025--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing, applauds the Ontario government for its recent decision to include the Dexcom G7 Continuous Glucose Monitoring (CGM) System as part of the Ontario Drug Benefit (ODB) program for eligible Ontarians who manage their diabetes with insulin.* Diabetes Canada estimates that 1.7 million people in Ontario are living with diabetes in 2024, with a significant portion requiring insulin for either type 1 or type 2 diabetes1. This highlights a broad need for support across both types of diabetes for insulin therapy optimization. This coverage expansion will grant access to Dexcom G7 to a broader population and make Dexcom G7 now the most covered CGM on government-funded programs in Ontario†,2 for people on insulin through the following programs: Ontario Drug Benefit (ODB) – for eligible residents on insulin aged 65+ or earlier if they: Live in a long-term care home, home for special care, or Community Home for Opportunity Are 24 or under without private insurance (OHIP+) Receive professional home and community care Get benefits from Ontario Works or ODSP Are enrolled in the Trillium Drug Program Assistive Devices Program (ADP) – for individuals with type 1 diabetes who meet the eligibility criteria. Private Insurance – most private insurance plans cover Dexcom G7 for anyone on insulin. Non-Insured Health Benefits (NIHB) – for eligible First Nations and Inuit clients on insulin. "This announcement represents a significant step forward for people managing diabetes in Ontario and their healthcare providers with more equitable access to Dexcom's life-changing CGM technology," says André Côté, Vice President and General Manager of Dexcom Canada. "By expanding coverage for Dexcom G7 under ODB, Ontario is recognizing the value of the #1 preferred glucose sensor by Canadian endocrinologists‡, 3 for the management of insulin-using patients." Dexcom G7 is the most accurate CGM with clinically proven outcomes§,2 including lowering A1C, reducing hyper-and hypoglycemia, and increasing time in range for people with type 1 or type 2 diabetes4-8. Featuring several unique alerts supporting safer insulin therapy, this increased access to Dexcom G7 is welcome news for both healthcare providers and their patients using insulin. "As an endocrinologist, I've seen firsthand how continuous glucose monitoring has transformed diabetes management," says Dr. Alexander Abitbol, Endocrinologist & Assistant Medical Director, LMC Healthcare. "Managing diabetes is very personal, and being able to offer patients a choice on the most appropriate CGM technology with features tailored to help them meet their individualized care goals is critical." Dexcom G7 allows individuals to easily see their glucose levels in real-time to make more informed insulin treatment decisions. Users can see directly how medications affect their levels and gain insights on what keeps their levels stable, empowering them to learn what works in order to feel their best and stay motivated over time. Discreet and easy to use, Dexcom G7 is the only sensor in Canada to offer these features for insulin therapy optimization and personalization for any lifestyle: Predictive Urgent Low Soon|| alert that can warn in advance of severe hypoglycemia9 Delay 1st High alert after a meal that may help reduce insulin stacking10,11 Waterproof sensor¶ Fast 30-minute sensor warm-up time Multiple sensor wear locations# Direct to Apple Watch functionality**– user can see glucose numbers right on their wrist As the #1 patient recommended CGM in Canada††,12, Dexcom G7 delivers both clinical and lifestyle benefits, and now more Ontarians than ever will have access to this technology for their diabetes management. To learn more about Dexcom G7 and the public and private coverage options available, please visit About Dexcom Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in continuous glucose monitoring for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently. Dexcom. Discover what you're made of. For more information, visit Category: IR _______________________________________ * For ODB eligible persons who are on insulin therapy for diabetes and who have a valid prescription for Dexcom G7 from a physician or nurse practitioner. Limit of 45 Dexcom G7 Sensors per eligible person per 365-day period. Dexcom G7 Receivers are also covered if there is no compatible smart device. For detailed coverage criteria, please visit † Dexcom G7 is the only CGM covered by ODB, ADP, most private insurance & NIHB for people on insulin. Eligibility and coverage vary by policy, plan, and payor. For insurance assistance call Dexcom Canada at 1-844-832-1810 with any questions. ‡ Based on a survey of Canadian Endocrinologists (n=41) § When compared with CGM systems commercially available in Canada as of October, 2023. Sensors worn on the back of the upper arm have been found to be slightly more accurate than sensors worn on the abdomen. || Audible and visual notification of predictive alert at 3.1 mmol/L within 20 minutes. ¶ The Dexcom G7 Sensor is waterproof and may be submerged under eight feet of water for up to 24 hours without failure when properly installed. # Indicated for wear on the back of the upper arm and abdomen for ages 2 years and older or the upper buttocks for ages 2-6 years old. ** Smart device sold separately. To view a list of compatible devices, visit Compatible smartphone is required to pair a new Dexcom G7 sensor with a compatible Apple Watch. †† Based on a comparison in NPS scores across major CGM brands 1 2 Dexcom, data on file, 2025 3 Q&A, Dexcom Canadian Endos Report Wave 1 2024 4 Beck, RW, et al. JAMA. 2017;317(4):371-378. 5 Beck RW, et al. Ann Intern Med. 2017;167(6):365-374. 6 Martens T, et al. JAMA. 2021;325(22):2262-2272. 7 Laffel LM, et al. JAMA. 2020;323(23):2388-2396. 8 Welsh JB, et al. J Diabetes Sci Technol. 2024;18(1):143-7. 9 Dexcom G7 User Guide. 10 Aly A, et al. Diabetes Technol. Ther. 2024;26(S2): A254-255. 11 Puhr S, et al. Diabetes Technol Ther. 2019;21(4):155-158. 12 DQ&A, Canada Diabetes Connections Patient Panel Report, H1 2024 View source version on Contacts Media Contact: Cole DouglasCdouglas@ 416.460.5480 Investor Contact: investor-relations@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
MIMEDX Announces Strategic Collaboration with Vaporox, Inc.
Relationship Establishes Co-Promotion and Co-Marketing of MIMEDX's Leading Placental Allograft Portfolio and Vaporox's Vaporous Hyperoxia Treatment Device MARIETTA, Ga., July 30, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) ('MIMEDX' or the 'Company') and Vaporox, Inc. ('Vaporox') today jointly announced a collaboration, whereby the companies will co-promote and co-market their wound care offerings. As part of the agreement, MIMEDX has made an investment in Vaporox and the Company has certain exclusivity rights related to potential acquisition discussions. Vaporox is a privately held, Denver-based company that has developed and is commercializing its patented Vaporous Hyperoxia Therapy ('VHT') device for treating chronic and hard-to-heal wounds. VHT delivers two healing modalities, ultrasonic mist and concentrated oxygen, in a single device and has received a 510(k) clearance from the U.S. Food & Drug Administration ('FDA') to treat nine types of wounds, including Diabetic Foot Ulcers ('DFUs'), Venous Leg Ulcers ('VLUs') and Pressure Ulcers (bed sores). 'We are thrilled to continue delivering on our strategic goal of greater portfolio diversification through this collaboration with Vaporox,' commented Joseph H. Capper, MIMEDX Chief Executive Officer. 'Together with our leading placental allografts, VHT will offer clinicians across numerous care settings another proven option to treat chronic, hard-to-heal wounds. We view this as a highly complementary addition that will help us grow in this important setting, where patients with difficult wounds often begin their recovery.' 'Vaporox is excited to partner with a market leader in wound care to expand awareness and adoption of our technology,' said Alan Sage, Chief Executive Officer of Vaporox. 'We believe co-promotion with MIMEDX will accelerate our market penetration and create a synergistic offering—allowing us to reach more patients with these highly complementary offerings.' VHT has been the subject of three IRB clinical studies, each of which demonstrated wound healing rates exceeding 80% at 20 weeks when combined with standard wound care. Additionally, Vaporox's VHT is an adjunct therapy that has shown promising signs of efficacy in real-world use cases with MIMEDX's Advanced Wound Care products, such as EPIFIX®. About Vaporox, technology represents a breakthrough in treating chronic wounds. The company is focused on superior healing outcomes while reducing costs across a wide range of healthcare settings. With strong clinical results and growing adoption, Vaporox empowers providers to restore hope and healing for patients suffering from chronic wounds. For additional information, please visit About MIMEDXMIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX is dedicated to providing a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company's vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit Contact:Matt NotarianniInvestor Relations470-304-7291mnotarianni@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
